TRIPLETE: a randomised phase III study of modified FOLFOXIRI plus panitumumab versus mFOLFOX6 plus panitumumab as initial therapy for patients with unresectable RAS and BRAF wild-type metastatic colorectal cancer

BACKGROUND: FOLFOXIRI plus bevacizumab is considered a standard option in the upfront treatment of clinically selected patients with metastatic colorectal cancer irrespective of RAS and BRAF molecular status. The randomised MACBETH and VOLFI studies showed that a modified FOLFOXIRI regimen in combin...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:ESMO Open
Autors principals: Borelli, Beatrice, Moretto, Roberto, Lonardi, Sara, Bonetti, Andrea, Antoniotti, Carlotta, Pietrantonio, Filippo, Masi, Gianluca, Burgio, Valentina, Marmorino, Federica, Salvatore, Lisa, Rossini, Daniele, Zaniboni, Alberto, Zucchelli, Gemma, Martignetti, Angelo, Di Battista, Monica, Pella, Nicoletta, Passardi, Alessandro, Boccaccino, Alessandra, Leone, Francesco, Colombo, Camilla, Granetto, Cristina, Vannini, Francesca, Marsico, Valentina Angela, Martinelli, Erika, Antonuzzo, Lorenzo, Vitello, Stefano, Delliponti, Laura, Boni, Luca, Cremolini, Chiara, Falcone, Alfredo
Format: Artigo
Idioma:Inglês
Publicat: BMJ Publishing Group 2018
Matèries:
Protocol
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6045747/
https://ncbi.nlm.nih.gov/pubmed/30018814
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/esmoopen-2018-000403
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars